Lyell Immunopharma, Inc. - LYEL
Ownership (Schedule 13D / 13G) · latest 50 filings
· Back to all files
Visible: 0
| Filed | Form | Reporting person | Percent | Shares | SEC |
|---|---|---|---|---|---|
| Nov 14, 2025 | SCHEDULE 13G/A | Foresite Capital Fund IV, L.P. | 4.2% | 800,339 | View |
| Nov 14, 2025 | SCHEDULE 13G/A | Foresite Capital Management IV, LLC | 4.2% | 800,339 | View |
| Nov 14, 2025 | SCHEDULE 13G/A | Foresite Capital Fund V, L.P. | 2.5% | 477,078 | View |
| Nov 14, 2025 | SCHEDULE 13G/A | Foresite Capital Management V, LLC | 2.5% | 477,078 | View |
| Nov 14, 2025 | SCHEDULE 13G/A | Foresite Capital Opportunity Fund V, L.P. | 0.9% | 177,199 | View |
| Nov 14, 2025 | SCHEDULE 13G/A | Foresite Capital Opportunity Management V, LLC | 0.9% | 177,199 | View |
| Nov 14, 2025 | SCHEDULE 13G/A | James B. Tananbaum | 7.6% | 1,454,616 | View |
| Nov 14, 2025 | SCHEDULE 13G/A | ARCH Venture Fund IX, L.P. | 13.0% | 2,759,072 | View |
| Nov 14, 2025 | SCHEDULE 13G/A | ARCH Venture Fund IX Overage, L.P. | 13.0% | 2,759,072 | View |
| Nov 14, 2025 | SCHEDULE 13G/A | ARCH Venture Fund XIII, L.P. | 13.0% | 2,759,072 | View |
| Nov 14, 2025 | SCHEDULE 13G/A | ARCH Venture Partners IX, L.P. | 13.0% | 2,759,072 | View |
| Nov 14, 2025 | SCHEDULE 13G/A | ARCH Venture Partners IX Overage, L.P. | 13.0% | 2,759,072 | View |
| Nov 14, 2025 | SCHEDULE 13G/A | ARCH Venture Partners IX, LLC | 13.0% | 2,759,072 | View |
| Nov 14, 2025 | SCHEDULE 13G/A | ARCH Venture Partners XIII, L.P. | 13.0% | 2,759,072 | View |
| Nov 14, 2025 | SCHEDULE 13G/A | ARCH Venture Partners XIII, LLC | 13.0% | 2,759,072 | View |
| Nov 14, 2025 | SCHEDULE 13G/A | Keith Crandell | 13.0% | 2,759,072 | View |
| Nov 14, 2025 | SCHEDULE 13G/A | Clinton Bybee | 8.6% | 1,820,634 | View |
| Nov 14, 2025 | SCHEDULE 13G/A | Robert Nelsen | 13.0% | 2,759,072 | View |
| Nov 14, 2025 | SCHEDULE 13G/A | Kristina Burow | 13.0% | 2,759,072 | View |
| Nov 14, 2025 | SCHEDULE 13G/A | Steven Gillis | 13.0% | 2,759,072 | View |
| Nov 14, 2025 | SCHEDULE 13G/A | Paul Berns | 4.4% | 938,438 | View |
| Nov 13, 2025 | SCHEDULE 13G | Innovative Cellular Therapeutics Holdings Ltd | 9.8% | 1,900,000 | View |
| Nov 12, 2025 | SCHEDULE 13G/A | Newton (PTC) Limited | 3.93% | 754,698 | View |
| Nov 12, 2025 | SCHEDULE 13G/A | Orland Properties Limited | 3.93% | 754,698 | View |
| Nov 12, 2025 | SCHEDULE 13G/A | Gemini GP Limited | 3.93% | 754,698 | View |
| Nov 12, 2025 | SCHEDULE 13G/A | Gemini Investments, L.P. | 3.93% | 754,698 | View |
Percent = "% of class represented by amount beneficially owned" for this reporting person in the filed 13D/13G.
Shares = reported beneficial ownership amount for the same row (not portfolio shares from 13F).
Amendments (/A) can repeat the same holder over time, so rows should not be summed.
Extraction is best-effort from filing text and can be missing or noisy; verify exact figures via the SEC link in each row.